Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

Alzai Health Corp. Completes Initial Public Offering

Early-stage AI diagnostics IPO raises $4M to fund Alzheimer's screening R&D and commercialization.

By The Northwire Desk — AI Analysis Jun 09, 2026 · 08:23 ALZI NaN
Executive Summary
  • Alzai Health Corp. successfully closed its initial public offering on June 9, 2026.
  • The company sold 10,125,000 units at $0.40 per unit, generating $4,050,000 in gross proceeds.
  • Each unit consists of one common share and one-half warrant exercisable at $0.60 per share until June 2028.
  • Warrants include an acceleration clause if the VWAP reaches $0.90 for 10 consecutive trading days.
  • Net proceeds are designated for research and development, sales and marketing, and general working capital.
  • Common shares resumed trading on the TSX Venture Exchange under the ticker ALZI following a brief halt.
Material Impact
  • This is a financing event that provides initial public market liquidity and seed capital.
  • The capital raise is modest ($4.05M gross), which is standard for early-stage ventures but insufficient for long-term commercialization without follow-on offerings.
  • Immediate dilution occurs via the 10.125M new shares issued, with additional potential dilution from warrants and agent warrants.
  • No operational, revenue, or product milestone impact is disclosed in this release; the company remains in the pre-revenue development phase.
ALZI · Price
Company Overview
  • Alzai Health Corp. develops an AI-driven, non-invasive Alzheimer’s disease risk screening solution.
  • The platform utilizes pre-existing clinical data to enable earlier diagnosis and intervention.
  • The company is in the early development stage, focusing on R&D and commercialization preparation.
Read the original news release →

More from NaN

Jun 05, 2026 · 16:15

AI-driven Alzheimer's screening startup prepares for TSXV debut

Financings Apr 22, 2026 · 16:17

Alzai Health Files Final Prospectus for $4M Best-Efforts IPO

Financings